7292-94-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-aminobenzyl)pyrimidine-2,4(1H,3H)-dione is used as a chemical intermediate for the synthesis of various drugs, due to its unique structure and reactivity.
Used in Antitumor Applications:
In the field of oncology, 1-(4-aminobenzyl)pyrimidine-2,4(1H,3H)-dione is used as an antitumor agent, given its potential to target and inhibit the growth of cancer cells.
Used in Neurological Disorder Treatment:
ABPD is also utilized in the treatment of neurological disorders, as it has shown promise in addressing the underlying causes and symptoms of certain conditions.
Used in Biological Imaging:
As a fluorescent probe, 1-(4-aminobenzyl)pyrimidine-2,4(1H,3H)-dione is used in biological imaging to help visualize and study cellular and molecular processes within living organisms.
Used in Metal Complexation Chemistry:
ABPD serves as a ligand in metal complexation chemistry, where it plays a crucial role in the formation and stabilization of metal complexes, which have various applications in catalysis, materials science, and pharmaceuticals.

Upstream product

• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 7263-86-7 1-(4-nitrobenzyl)uracil 

Downstream Products

• 339985-31-8 1-(4-(cholesterylcarbonylamino)benzyl)uracil 

Relevant academic research and scientific papers

NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE

The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product

Gel formation properties of a uracil-appended cholesterol gelator and cooperative effects of the complementary nucleobases

We designed and synthesized a uracil-appended cholesterol gelator (1) in order to control the gel stability and the gel morphology by addition of the complementary and non-complementary nucleobase derivatives. Compound 1 forms columnar stacks in cyclohexane due to the van der Waals interaction (cholesterol-cholesterol interaction) and the intergelator hydrogen bonding between uracil moieties. Addition of a 'monomeric' adenosine (3) into the gel only decreases the stability with increasing the concentration. The destabilization is ascribed to a lack of intergelator hydrogen bonding accompanied with forming the complementary base pairs between 1 and 3. In contrast, addition of adenine-appended cholesterol (7) induces a different behavior; with increasing 7 concentration the mixed gel is initially stabilized and then destabilized, giving rise to a maximum at the ratio of 1/7=1:1 for the Tgel plot. One may consider, therefore, that when the additive has a common, column-forming cholesterol moiety, the cholesterol-cholesterol interaction can operate cooperatively with the complementary base pairing. In addition, the gel fiber structure is clearly changed by the addition of 7. Taking the fact that there is no report for such an additive effect inducing a structural change with maintaining the gel stability into consideration, our attempt combining cholesterol columnar stacks with the nucleobase additives provides a new methodology to control the stability and the morphology of organogels.